سوق اختبارات التشخيص الأوروبية - اتجاهات الصناعة والتوقعات حتى عام 2030

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF EUROPE DIAGNOSTICS TESTS MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATION

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 KEY TAKEAWAYS

2.2 ARRIVING AT THE EUROPE DIAGNOSTICS TESTS MARKET SIZE

2.2.1 VENDOR POSITIONING GRID

2.2.2 TECHNOLOGY LIFE LINE CURVE

2.2.3 TRIPOD DATA VALIDATION MODEL

2.2.4 MARKET GUIDE

2.2.5 MULTIVARIATE MODELLING

2.2.6 TOP TO BOTTOM ANALYSIS

2.2.7 CHALLENGE MATRIX

2.2.8 APPLICATION COVERAGE GRID

2.2.9 STANDARDS OF MEASUREMENT

2.2.10 VENDOR SHARE ANALYSIS

2.2.11 SALES VOLUME DATA

2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS

2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES

2.3 EUROPE DIAGNOSTICS TESTS MARKET: RESEARCH SNAPSHOT

2.4 ASSUMPTIONS

3 MARKET OVERVIEW

3.1 DRIVERS

3.2 RESTRAINTS

3.3 OPPORTUNITIES

3.4 CHALLENGES

4 EXECUTIVE SUMMARY

5 PREMIUM INSIGHTS

5.1 PESTEL ANALYSIS

5.2 PORTER'S FIVE FORCES MODEL

6 INDUSTRY INSIGHTS

6.1 MICRO AND MACRO ECONOMIC FACTORS

6.2 PENETRATION AND GROWTH PROSPECT MAPPING

6.3 KEY PRICING STRATEGIES

6.4 INTERVIEWS WITH SPECIALIST

6.5 ANALYIS AND RECOMMENDATION

7 INTELLECTUAL PROPERTY (IP) PORTFOLIO

7.1 PATENT QUALITY AND STRENGTH

7.2 PATENT FAMILIES

7.3 LICENSING AND COLLABORATIONS

7.4 COMPETITIVE LANDSCAPE

7.5 IP STRATEGY AND MANAGEMENT

7.6 OTHER

8 COST ANALYSIS BREAKDOWN

9 TECHNOLOGY ROADMAP

10 INNOVATION TRACKER AND STRATEGIC ANALYSIS

10.1 MAJOR DEALS AND STRATEGIC ALLIANCES ANALYSIS

10.1.1 JOINT VENTURES

10.1.2 MERGERS AND ACQUISITIONS

10.1.3 LICENSING AND PARTNERSHIP

10.1.4 TECHNOLOGY COLLABORATIONS

10.1.5 STRATEGIC DIVESTMENTS

10.2 NUMBER OF PRODUCTS IN DEVELOPMENT

10.3 STAGE OF DEVELOPMENT

10.4 TIMELINES AND MILESTONES

10.5 INNOVATION STRATEGIES AND METHODOLOGIES

10.6 RISK ASSESSMENT AND MITIGATION

10.7 FUTURE OUTLOOK

11 REGULATORY COMPLIANCE

11.1 REGULATORY AUTHORITIES

11.2 REGULATORY CLASSIFICATIONS

11.2.1 CLASS I

11.2.2 CLASS II

11.2.3 CLASS III

11.3 REGULATORY SUBMISSIONS

11.4 INTERNATIONAL HARMONIZATION

11.5 COMPLIANCE AND QUALITY MANAGEMENT SYSTEMS

11.6 REGULATORY CHALLENGES AND STRATEGIES

12 REIMBURSEMENT FRAMEWORK

13 OPPUTUNITY MAP ANALYSIS

14 INSTALLED BASE DATA

15 VALUE CHAIN ANALYSIS

16 HEALTHCARE ECONOMY

16.1 HEALTHCARE EXPENDITURE

16.2 CAPITAL EXPENDITURE

16.3 CAPEX TRENDS

16.4 CAPEX ALLOCATION

16.5 FUNDING SOURCES

16.6 INDUSTRY BENCHMARKS

16.7 GDP RATION IN OVERALL GDP

16.8 HEALTHCARE SYSTEM STRUCTURE

16.9 GOVERNMENT POLICIES

16.1 ECONOMIC DEVELOPMENT

17 EUROPE DIAGNOSTICS TESTS MARKET, BY TYPE

17.1 OVERVIEW

17.2 ROUTINE TESTS

17.2.1 GLUCOSE TEST

17.2.2 INFECTIOUS DISEASES TEST

17.2.3 CBC TEST

17.2.4 BLOOD CULTURE TEST

17.2.5 SYPHILIS TEST

17.2.6 UREA TEST

17.2.7 C-REACTIVE PROTEIN TEST

17.2.8 ANTIGEN TEST

17.2.9 HBA1C TEST

17.2.10 PREGNANCY TEST

17.2.11 LIPID PROFILE TEST

17.2.12 ELECTROLYTES TEST

17.2.13 LIVER FUNCTION TEST

17.2.14 STOOL HELICOBACTER PYLORI TEST

17.2.15 CALCIUM TEST

17.2.16 CROSSMATCH TEST

17.2.17 THYROID FUNCTION TEST

17.2.18 STOOL MICROSCOPY TEST

17.2.19 URINE MICROSCOPY TEST

17.2.20 UNIT PACKED RBCS TEST

17.2.21 ESR TEST

17.2.22 OTHERS

17.3 SPECIALIZED TESTS

17.3.1 MOLECULAR DIAGNOSTIC TESTS

17.3.2 IMMUNOLOGICAL TESTS

17.3.3 GENETIC TESTS

17.3.4 TOXICOLOGY TESTS

17.3.5 OTHERS

18 EUROPE DIAGNOSTICS TESTS MARKET, BY COMPONENT

18.1 OVERVIEW

18.2 PRODUCTS

18.2.1 INSTRUMENTS

18.2.1.1. BY TYPE

18.2.1.1.1. IN-VITRO DIAGNOSTIC INSTRUMENT

18.2.1.1.1.1 IMMUNOASSAY INSTRUMENT

18.2.1.1.1.1.1. BY TYPE

A. ELISA READERS

B. CLIA ANALYZERS

C. OTHERS

18.2.1.1.1.1.2. BY MODE

A. AUTOMATED

B. SEMI-AUTOMATED

C. MANUAL

18.2.1.1.1.1.3. BY MODALITY

A. BENCHTOP

B. FLOOR-STANDING

C. MODULAR

18.2.1.1.1.2 CLINICAL CHEMISTRY INSTRUMENT

18.2.1.1.1.2.1. BY TYPE

A. SPECTROPHOTOMETERS

B. ELECTROLYTE ANALYZERS

C. BLOOD GAS ANALYZERS

D. COAGULATION ANALYZERS

E. MICROPLATE READERS

18.2.1.1.1.2.2. BY MODE

A. AUTOMATED

B. SEMI-AUTOMATED

C. MANUAL

18.2.1.1.1.2.3. BY MODALITY

A. BENCHTOP

B. FLOOR-STANDING

C. MODULAR

18.2.1.1.1.3 HEMATOLOGY INSTRUMENT

18.2.1.1.1.3.1. BY MODE

A. AUTOMATED

B. SEMI-AUTOMATED

C. MANUAL

18.2.1.1.1.3.2. BY MODALITY

A. BENCHTOP

B. FLOOR-STANDING

C. MODULAR

18.2.1.1.1.4 MOLECULAR DIAGNOSTIC INSTRUMENT

18.2.1.1.1.4.1. BY MODE

A. PCR INSTRUMENTS

B. NGS INSTRUMENTS

C. MICROARRAY INSTRUMENTS

D. ISOTHERMAL AMPLIFICATION INSTRUMENTS

E. NUCLEIC ACID EXTRACTION INSTRUMENTS

F. HYBRIDIZATION INSTRUMENTS

18.2.1.1.1.4.2. BY MODE

A. AUTOMATED

B. SEMI-AUTOMATED

C. MANUAL

18.2.1.1.1.4.3. BY MODALITY

A. BENCHTOP

B. FLOOR-STANDING

C. MODULAR

18.2.1.1.1.5 OTHERS

18.2.1.1.2. POINT OF CARE TESTING INSTRUMENT

18.2.1.1.2.1 BLOOD GLUCOSE MONITORING DEVICES

18.2.1.1.2.2 RAPID DIAGNOSTIC TEST DEVICES

18.2.1.1.2.3 CARDIAC MARKER DEVICES

18.2.1.1.2.4 INFECTIOUS DISEASE TESTING DEVICES

18.2.1.1.2.5 URINE ANALYSIS DEVICES

18.2.1.2. OTHER

18.2.2 KITS AND REAGENTS

18.2.2.1. PREGNANCY TESTING KITS

18.2.2.1.1. STRIPS

18.2.2.1.2. CASETTES

18.2.2.1.3. MIDSTREAM

18.2.2.1.4. DIP CARD

18.2.2.1.5. OTHERS

18.2.2.2. URINALYSIS TESTING KITS

18.2.2.2.1. CASSETTES TESTS

18.2.2.2.2. STRIP TESTS

18.2.2.3. GLUCOSE MONITORING KITS

18.2.2.3.1. STRIPS

18.2.2.3.2. CARTRIDGES

18.2.2.4. CARDIAC ASSAYS

18.2.2.4.1. TROPONIN

18.2.2.4.2. BNP

18.2.2.4.3. MYOGLOBIN

18.2.2.4.4. OTHERS

18.2.2.5. INFECTIOUS DISEASE TESTING KITS

18.2.2.5.1. HEPATITIS

18.2.2.5.2. INFLUENZA

18.2.2.5.3. HIV/AIDS

18.2.2.5.4. TUBERCULOSIS

18.2.2.5.5. HOSPITAL ACQUIRED INFECTIONS

18.2.2.5.6. COVID-19

18.2.2.5.7. OTHERS

18.2.2.6. DRUG TEST KITS

18.2.2.6.1. MARIJUANA

18.2.2.6.2. AMPHETAMINES

18.2.2.6.3. BARBITUATES

18.2.2.6.4. ANTI DEPRESSANTS

18.2.2.6.5. PCP

18.2.2.6.6. METHADONE

18.2.2.6.7. OTHERS

18.2.2.7. OTHERS

18.2.3 CONSUMABLES

18.2.3.1. NEEDLES AND SYRINGES

18.2.3.2. BLOOD COLLECTION DEVICES

18.2.3.3. MEDIA CULTURE

18.2.3.3.1. BROTH

18.2.3.3.2. AGAR

18.2.3.3.3. OTHERS

18.2.3.4. STAINS

18.2.3.4.1. GRAM STAINS

18.2.3.4.2. MYCOBACTERIA STAINS

18.2.3.4.3. FUNGAL STAINS

18.2.3.4.4. OTHERS

18.2.3.5. CONTROLS & CALIBRATORS

18.2.3.6. PLATES

18.2.3.7. OTHERS

18.3 SERVICES

19 EUROPE DIAGNOSTICS TESTS MARKET, BY TECHNOLOGY

19.1 OVERVIEW

19.2 PCR-BASED

19.2.1 REAL-TIME PCR

19.2.2 NESTED PCR

19.2.3 MULTIPLEX PCR

19.2.4 QUANTITATIVE PCR

19.2.5 OTHERS

19.3 IMMUNOASSAY-BASED

19.3.1 LATERAL FLOW IMMUNOASSAY

19.3.1.1. SANDWICH ASSAYS

19.3.1.2. COMPETITIVE ASSAYS

19.3.2 PAPER-BASED IMMUNOASSAYS

19.3.3 OTHERS

19.4 CHROMATOGRAPHY-BASED

19.4.1 LC-MS

19.4.2 GC-MS

19.4.3 LC-MS/MS

19.5 SPECTROSCOPY-BASED

19.5.1 MASS SPECTROMETRY

19.5.2 RAMAN SPECTROSCOPY

19.5.3 OPTICAL SPECTROSCOPY

19.5.4 OTHERS

19.6 MICROFLUIDICS

19.6.1 LUCIFERASE IMMUNOPRECIPITATION SYSTEMS (LIPS)

19.6.2 PAPER-BASED MICROFLUDICS

19.7 NEXT GENE SEQUENCING

19.7.1 WHOLE GENOME SEQUENCING

19.7.2 TARGETED RESEQUENCING

19.7.3 WHOLE EXOME SEQUENCING

19.7.4 RNA SEQUENCING

19.7.5 OTHERS

19.8 OTHERS

20 EUROPE DIAGNOSTICS TESTS MARKET, BY MODE OF TESTING

20.1 OVERVIEW

20.2 PRESCRIPTION-BASED TESTING

20.3 OTC TESTING

21 EUROPE DIAGNOSTICS TESTS MARKET, BY APPLICATION

21.1 OVERVIEW

21.2 CARDIOLOGY

21.3 ONCOLOGY

21.4 NEUROLOGY

21.5 ORTHOPEDICS

21.6 GASTROENTROLOGY

21.7 GYNECOLOGY

21.8 ODONTOLOGY

21.9 OTHERS

22 EUROPE DIAGNOSTICS TESTS MARKET, BY SAMPLE TYPE

22.1 BLOOD

22.2 URINE

22.3 SALIVA

22.4 RESPIRATORY SAMPLES

22.5 STOOL

22.6 BIOPSY

22.7 OTHERS

23 EUROPE DIAGNOSTICS TESTS MARKET, BY TESTING SITE

23.1 OVERVIEW

23.2 AT HOME TESTING

23.3 LABROATORIES BASED TESTING

24 EUROPE DIAGNOSTICS TESTS MARKET, BY TESTING TYPE

24.1 OVERVIEW

24.2 BIOCHEMISTRY

24.3 HEMATOLOGY

24.4 MICROBIOLOGY

24.5 HISTOPATHOLOGY

24.6 OTHERS

25 EUROPE DIAGNOSTICS TESTS MARKET, BY AGE

25.1 OVERVIEW

25.2 PEDIATRIC

25.3 ADULT

25.4 GERIARTIC

26 EUROPE DIAGNOSTICS TESTS MARKET, BY END USER

26.1 OVERVIEW

26.2 HOSPITALS

26.2.1 PUBLIC

26.2.2 PRIVATE

26.3 DIAGNOSTIC CENTER

26.4 ACADEMIC LABS & INSTITUTES

26.5 RESEARCH INSTITUTE

26.6 HOMECARE

26.7 BLOOD BANKS

26.8 SPECILATY CLINICS

26.9 AMBULATORY SURGICAL CENTERS (ASCS)

26.1 OTHERS

27 EUROPE DIAGNOSTICS TESTS MARKET, BY DISTRIBUTION CHANNEL

27.1 OVERVIEW

27.2 DIRECT TENDERS

27.3 RETAIL SALES

27.3.1 ONLINE

27.3.2 OFFLINE

27.4 OTHERS

28 EUROPE DIAGNOSTICS TESTS MARKET, COMPANY LANDSCAPE

28.1 COMPANY SHARE ANALYSIS: EUROPE

28.2 MERGERS & ACQUISITIONS

28.3 NEW PRODUCT DEVELOPMENT & APPROVALS

28.4 EXPANSIONS

28.5 REGULATORY CHANGES

28.6 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS

29 EUROPE DIAGNOSTICS TESTS MARKET, SWOT AND DBMR ANALYSIS

30 EUROPE DIAGNOSTICS TESTS MARKET, BY COUNTRY

EUROPE DIAGNOSTICS TESTS MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)

30.1 EUROPE

30.1.1 GERMANY

30.1.2 FRANCE

30.1.3 U.K.

30.1.4 HUNGARY

30.1.5 LITHUANIA

30.1.6 AUSTRIA

30.1.7 IRELAND

30.1.8 NORWAY

30.1.9 POLAND

30.1.10 ITALY

30.1.11 SPAIN

30.1.12 RUSSIA

30.1.13 TURKEY

30.1.14 NETHERLANDS

30.1.15 SWITZERLAND

30.1.16 REST OF EUROPE

30.2 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES

31 EUROPE DIAGNOSTICS TESTS MARKET, COMPANY PROFILE

31.1 ABBOTT

31.1.1 COMPANY OVERVIEW

31.1.2 REVENUE ANALYSIS

31.1.3 GEOGRAPHIC PRESENCE

31.1.4 PRODUCT PORTFOLIO

31.1.5 RECENT DEVELOPMENTS

31.2 BIO-RAD LABORATORIES, INC.

31.2.1 COMPANY OVERVIEW

31.2.2 REVENUE ANALYSIS

31.2.3 GEOGRAPHIC PRESENCE

31.2.4 PRODUCT PORTFOLIO

31.2.5 RECENT DEVELOPMENTS

31.3 DANAHER

31.3.1 COMPANY OVERVIEW

31.3.2 REVENUE ANALYSIS

31.3.3 GEOGRAPHIC PRESENCE

31.3.4 PRODUCT PORTFOLIO

31.3.5 RECENT DEVELOPMENTS

31.4 BD

31.4.1 COMPANY OVERVIEW

31.4.2 REVENUE ANALYSIS

31.4.3 GEOGRAPHIC PRESENCE

31.4.4 PRODUCT PORTFOLIO

31.4.5 RECENT DEVELOPMENTS

31.5 F. HOFFMANN-LA ROCHE LTD

31.5.1 COMPANY OVERVIEW

31.5.2 REVENUE ANALYSIS

31.5.3 GEOGRAPHIC PRESENCE

31.5.4 PRODUCT PORTFOLIO

31.5.5 RECENT DEVELOPMENTS

31.6 EKF DIAGNOSTICS

31.6.1 COMPANY OVERVIEW

31.6.2 REVENUE ANALYSIS

31.6.3 GEOGRAPHIC PRESENCE

31.6.4 PRODUCT PORTFOLIO

31.6.5 RECENT DEVELOPMENTS

31.7 SIEMENS HEALTHINEERS

31.7.1 COMPANY OVERVIEW

31.7.2 REVENUE ANALYSIS

31.7.3 GEOGRAPHIC PRESENCE

31.7.4 PRODUCT PORTFOLIO

31.7.5 RECENT DEVELOPMENTS

31.8 THERMO FISHER SCIENTIFIC INC.

31.8.1 COMPANY OVERVIEW

31.8.2 REVENUE ANALYSIS

31.8.3 GEOGRAPHIC PRESENCE

31.8.4 PRODUCT PORTFOLIO

31.8.5 RECENT DEVELOPMENTS

31.9 ACON LABORATORIES, INC.

31.9.1 COMPANY OVERVIEW

31.9.2 REVENUE ANALYSIS

31.9.3 GEOGRAPHIC PRESENCE

31.9.4 PRODUCT PORTFOLIO

31.9.5 RECENT DEVELOPMENTS

31.1 BIOMEDOMICS INC

31.10.1 COMPANY OVERVIEW

31.10.2 REVENUE ANALYSIS

31.10.3 GEOGRAPHIC PRESENCE

31.10.4 PRODUCT PORTFOLIO

31.10.5 RECENT DEVELOPMENTS

31.11 QUIDELORTHO CORPORATION.

31.11.1 COMPANY OVERVIEW

31.11.2 REVENUE ANALYSIS

31.11.3 GEOGRAPHIC PRESENCE

31.11.4 PRODUCT PORTFOLIO

31.11.5 RECENT DEVELOPMENTS

31.12 ARKRAY, INC.

31.12.1 COMPANY OVERVIEW

31.12.2 REVENUE ANALYSIS

31.12.3 GEOGRAPHIC PRESENCE

31.12.4 PRODUCT PORTFOLIO

31.12.5 RECENT DEVELOPMENTS

31.13 STRECK

31.13.1 COMPANY OVERVIEW

31.13.2 REVENUE ANALYSIS

31.13.3 GEOGRAPHIC PRESENCE

31.13.4 PRODUCT PORTFOLIO

31.13.5 RECENT DEVELOPMENTS

31.14 PERKINELMER

31.14.1 COMPANY OVERVIEW

31.14.2 REVENUE ANALYSIS

31.14.3 GEOGRAPHIC PRESENCE

31.14.4 PRODUCT PORTFOLIO

31.14.5 RECENT DEVELOPMENTS

31.15 DIASORIN S.P.A

31.15.1 COMPANY OVERVIEW

31.15.2 REVENUE ANALYSIS

31.15.3 GEOGRAPHIC PRESENCE

31.15.4 PRODUCT PORTFOLIO

31.15.5 RECENT DEVELOPMENTS

31.16 BIOHIT HEALTHCARE LTD

31.16.1 COMPANY OVERVIEW

31.16.2 REVENUE ANALYSIS

31.16.3 GEOGRAPHIC PRESENCE

31.16.4 PRODUCT PORTFOLIO

31.16.5 RECENT DEVELOPMENTS

31.17 MICROGEN, INC.

31.17.1 COMPANY OVERVIEW

31.17.2 REVENUE ANALYSIS

31.17.3 GEOGRAPHIC PRESENCE

31.17.4 PRODUCT PORTFOLIO

31.17.5 RECENT DEVELOPMENTS

31.18 TRINITY BIOTECH IRELAND

31.18.1 COMPANY OVERVIEW

31.18.2 REVENUE ANALYSIS

31.18.3 GEOGRAPHIC PRESENCE

31.18.4 PRODUCT PORTFOLIO

31.18.5 RECENT DEVELOPMENTS

31.19 SYSMEX EUROPE SE

31.19.1 COMPANY OVERVIEW

31.19.2 REVENUE ANALYSIS

31.19.3 GEOGRAPHIC PRESENCE

31.19.4 PRODUCT PORTFOLIO

31.19.5 RECENT DEVELOPMENTS

31.2 QIAGEN

31.20.1 COMPANY OVERVIEW

31.20.2 REVENUE ANALYSIS

31.20.3 GEOGRAPHIC PRESENCE

31.20.4 PRODUCT PORTFOLIO

31.20.5 RECENT DEVELOPMENTS

31.21 BIOMÉRIEUX SA

31.21.1 COMPANY OVERVIEW

31.21.2 REVENUE ANALYSIS

31.21.3 GEOGRAPHIC PRESENCE

31.21.4 PRODUCT PORTFOLIO

31.21.5 RECENT DEVELOPMENTS

31.22 CHEMBIO DIAGNOSTICS, INC

31.22.1 COMPANY OVERVIEW

31.22.2 REVENUE ANALYSIS

31.22.3 GEOGRAPHIC PRESENCE

31.22.4 PRODUCT PORTFOLIO

31.22.5 RECENT DEVELOPMENTS

31.23 PTS DIAGNOSTICS

31.23.1 COMPANY OVERVIEW

31.23.2 REVENUE ANALYSIS

31.23.3 GEOGRAPHIC PRESENCE

31.23.4 PRODUCT PORTFOLIO

31.23.5 RECENT DEVELOPMENTS

31.24 AGILENT TECHNOLOGIES, INC.

31.24.1 COMPANY OVERVIEW

31.24.2 REVENUE ANALYSIS

31.24.3 GEOGRAPHIC PRESENCE

31.24.4 PRODUCT PORTFOLIO

31.24.5 RECENT DEVELOPMENTS

31.25 ILLUMINA, INC.

31.25.1 COMPANY OVERVIEW

31.25.2 REVENUE ANALYSIS

31.25.3 GEOGRAPHIC PRESENCE

31.25.4 PRODUCT PORTFOLIO

31.25.5 RECENT DEVELOPMENTS

31.26 EXACT SCIENCES CORPORATION

31.26.1 COMPANY OVERVIEW

31.26.2 REVENUE ANALYSIS

31.26.3 GEOGRAPHIC PRESENCE

31.26.4 PRODUCT PORTFOLIO

31.26.5 RECENT DEVELOPMENTS

31.27 MYRIAD GENETICS, INC.

31.27.1 COMPANY OVERVIEW

31.27.2 REVENUE ANALYSIS

31.27.3 GEOGRAPHIC PRESENCE

31.27.4 PRODUCT PORTFOLIO

31.27.5 RECENT DEVELOPMENTS

31.28 QUEST DIAGNOSTICS INCORPORATED.

31.28.1 COMPANY OVERVIEW

31.28.2 REVENUE ANALYSIS

31.28.3 GEOGRAPHIC PRESENCE

31.28.4 PRODUCT PORTFOLIO

31.28.5 RECENT DEVELOPMENTS

31.29 LABORATORY CORPORATION OF AMERICA HOLDINGS.

31.29.1 COMPANY OVERVIEW

31.29.2 REVENUE ANALYSIS

31.29.3 GEOGRAPHIC PRESENCE

31.29.4 PRODUCT PORTFOLIO

31.29.5 RECENT DEVELOPMENTS

31.3 PHC HOLDINGS CORPORATION

31.30.1 COMPANY OVERVIEW

31.30.2 REVENUE ANALYSIS

31.30.3 GEOGRAPHIC PRESENCE

31.30.4 PRODUCT PORTFOLIO

31.30.5 RECENT DEVELOPMENTS

32 RELATED REPORTS

33 CONCLUSION

34 QUESTIONNAIRE

35 ABOUT DATA BRIDGE MARKET RESEARCH